



THE OTIVATO® TRIAL

Objective:

To assess the effect of bronchodilators on activity-related breathlessness.



Background:

Breathlessness is a key feature of COPD that can lead to inactivity and poor outcomes.



Study design:

OTIVATO® compared the effects of T/O and Tio in patients with COPD.



Conclusions:

T/O improves breathlessness during walking in patients with COPD by improving lung function and reducing hyperinflation.

This may allow patients to walk for longer before being limited by symptoms.

3-min CSST = 3-minute constant speed shuttle test; T/O, tiotropium/olodaterol; Tio, tiotropium

O'Donnell D, et al. Proc Am Thorac Soc. 2006;3:180–184; Victorson DE, et al. Value in Health. 2009;12:1018–1025; Casaburi R, et al. Proc Am Thorac Soc. 2011;8:334–337; Garcia-Aymerich J, et al. Thorax. 2006;61:772–778; Global Initiative for Chronic Obstructive Lung Disease 2019; available at <https://goldcopd.org>; Maltais F, et al. Eur Respir J. 2019; doi: 10.1183/13993003.02049-2018